NovoCureNVCR
About: NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Employees: 1,453
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
303% more call options, than puts
Call options by funds: $22.4M | Put options by funds: $5.55M
13% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 69
11% more capital invested
Capital invested by funds: $1.43B [Q1] → $1.59B (+$164M) [Q2]
1.37% more ownership
Funds ownership: 84.99% [Q1] → 86.36% (+1.37%) [Q2]
1% less funds holding
Funds holding: 236 [Q1] → 234 (-2) [Q2]
4% less first-time investments, than exits
New positions opened: 46 | Existing positions closed: 48
33% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Evercore ISI Group Vijay Kumar 60% 1-year accuracy 24 / 40 met price target | 23%upside $18 | In-Line Maintained | 1 Oct 2024 |
Wells Fargo Larry Biegelsen 62% 1-year accuracy 8 / 13 met price target | 173%upside $40 | Overweight Maintained | 26 Jul 2024 |
HC Wainwright & Co. Emily Bodnar 27% 1-year accuracy 26 / 97 met price target | 64%upside $24 | Neutral Maintained | 26 Jul 2024 |